Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Appl Microbiol Biotechnol ; 99(17): 7059-68, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25994255

ABSTRACT

The potential of adherent Madin Darby Canine Kidney (MDCK) cells for the production of influenza viruses and canine adenovirus type 2 (CAV-2) for vaccines or gene therapy approaches has been shown. Recently, a new MDCK cell line (MDCK.SUS2) that was able to grow in suspension in a fully defined system was established. In this work, we investigated whether the new MDCK.SUS2 suspension cell line is suitable for the amplification of CAV-2 under serum-free culture conditions. Cell growth performance and CAV-2 production were evaluated in three serum-free media: AEM, SMIF8, and EXCELL MDCK. CAV-2 production in shake flasks was maximal when AEM medium was used, resulting in an amplification ratio of infectious particles (IP) of 142 IP out/IP in and volumetric and cell-specific productivities of 2.1 × 10(8) IP/mL and 482 IP/cell, respectively. CAV-2 production was further improved when cells were cultivated in a 0.5-L stirred tank bioreactor. To monitor infection and virus production, cells were analyzed by flow cytometry. A correlation between the side scatter measurement and CAV-2 productivity was found, which represents a key feature to determine the best harvesting time during process development of gene therapy vectors that do not express reporter genes. This work demonstrates that MDCK.SUS2 is a suitable cell substrate for CAV-2 production, constituting a step forward in developing a production process transferable to industrial scales. This could allow for the production of high CAV-2 titers either for vaccination or for gene therapy purposes.


Subject(s)
Adenoviruses, Canine/growth & development , Culture Media, Serum-Free , Virus Cultivation/methods , Animals , Bioreactors , Cell Proliferation , Dogs , Madin Darby Canine Kidney Cells
2.
J Biotechnol ; 127(3): 452-61, 2007 Jan 10.
Article in English | MEDLINE | ID: mdl-16959354

ABSTRACT

Rotavirus like particles (RLPs) constitute a potential vaccine for the prevention of rotavirus disease, responsible for the death of more than half a million children each year. Increasing demands for pre-clinical trials material require the development of reproducible, scaleable and cost-effective purification strategies as alternatives to the traditional laboratory scale CsCl density gradient ultracentrifugation methods commonly used for the purification of these complex particles. Self-assembled virus like particles (VLPs) composed by VP2, VP6 and VP7 rotavirus proteins (VLPs 2/6/7) were produced in 5l scale using the insect cells/baculovirus expression system. A purification process using depth filtration, ultrafiltration and size exclusion chromatography as stepwise unit operations was developed. Removal of non-assembled rotavirus proteins, concurrently formed particles (RLP 2/6), particle aggregates and products of particle degradation due to shear was achieved. Particle stability during storage was studied and assessed using size exclusion chromatography as an analytical tool. Formulations containing either glycerol (10% v/v) or trehalose (0.5 M) were able to maintain 75% of intact triple layered VLPs, at 4 degrees C, up to 4 months. The overall recovery yield was 37% with removal of 95% of host cell proteins and 99% of the host cell DNA, constituting a promising strategy for the downstream processing of other VLPs.


Subject(s)
Capsid Proteins/biosynthesis , Recombinant Proteins/biosynthesis , Rotavirus Vaccines/biosynthesis , Rotavirus Vaccines/isolation & purification , Rotavirus , Virus Assembly , Animals , Baculoviridae/genetics , Capsid Proteins/chemistry , Capsid Proteins/genetics , Capsid Proteins/isolation & purification , Humans , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Rotavirus/genetics , Rotavirus/ultrastructure , Rotavirus Infections/genetics , Rotavirus Infections/prevention & control , Rotavirus Vaccines/chemistry , Rotavirus Vaccines/genetics , Rotavirus Vaccines/therapeutic use , Spodoptera/cytology , Spodoptera/genetics , Virus Assembly/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...